drugset / Trial / NCT01417767
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) to decitabine in the treatment of higher-risk myelodysplastic syndromes(MDS).
Timeline
- Start
- 2011-09
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 25 mg | Intravenous |
| Comparator | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Homoharringtonine | Small molecule | 1 mg | Intravenous |